• Santhera Pharmaceuticals AG, of Liestal, Switzerland, said it obtained an exclusive license from the National Institutes of Health (NIH) to rights on a patent granted in the U.S. for the use of idebenone for the treatment of primary aggressive multiple sclerosis.